Engineered natural killer (NK) cells represent a promising option for immune therapy option
due to their immediate availability in allogeneic settings. Severe acute diseases, such as …

The clinical presentations of COVID-19 may range from an asymptomatic or mild infection to
a critical or fatal disease. Several host factors such as elderly age, male gender, and …

Background This exploratory study investigated four repurposed anti-infective drug
regimens in outpatients with COVID-19. Methods This phase 2, single centre, randomised …

Introduction Venezuelan, eastern, and western equine encephalitis viruses (VEEV, EEEV,
and WEEV) are mosquito-borne New World alphaviruses that cause encephalitis in equids …

One of the most recently described clinical associations with SARS-CoV-2 infection is
rebound COVID-19, which occurs between five and eight days following the cessation of …

SARS-CoV-2 is the causative agent of COVID-19 and is responsible for the current global
pandemic. The viral genome contains 5 major open reading frames of which the largest …

Vaccines remain the cornerstone of medical prevention and are highly effective in reducing
the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the …

Abstract On December 22, 2021, the United States Food and Drug Administration approved
the first main protease inhibitor, ie, oral antiviral nirmatrelvir (PF-07321332)/ritonavir …

Introduction The emergence of the Omicron SARS-CoV-2 variant of concern in late
November 2021 presaged yet another stage of the COVID-19 pandemic. Paxlovid, a co …

The continuing transmission of coronavirus disease 2019 (COVID-19) remains a world-wide
21st-century public health emergency of concern. Severe acute respiratory syndrome …